Advances in Targeted Therapy for R/R CLL

Nicole Lamanna, MD, and Nirav N. Shah, MD, discuss the chronic lymphocytic leukemia treatment (CLL) landscape, including risk factors and treatment options.

Dr Lamanna introduces covalent BTK inhibitors and their use in patients with CLL

Dr Lamanna explains the challenges associated with BTK inhibitors.

Nicole Lamanna, MD, continues her discussion on BTK inhibitor challenges.

Dr Shah introduces non-covalent BTK inhibitors and clinical findings from their use in the CLL landscape.

Dr Shah explains the clinical implications of using BTK inhibitors for CLL treatment.

Dr Lamanna expands on BTK clinical implications within CLL therapy.

Two experts discuss the use of BTK inhibitors in the treatment of other B-cell malignancies.

Nicole Lamanna, MD, and Nirav N. Shah, MD, conclude with their thoughts on the future of BTK inhibitors in CLL.